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22700 diabetic patients in Madrid was used to estimate transition probabilities in 
the model. Time horizon was 10 years. Prices were taken from the health care tariffs 
published by the Regional Health Service in Madrid and from Spanish literature. They 
were updated to 2013 price levels and adjusted to subsequent years by a 3% infla-
tion rate. We used the perspective of the Regional Health Service in Madrid (public 
payer). Results: The model included an acute event and 3 health states. The increase 
in total costs in 10 years was € 1,328 per DM patient (133 € per year). In patients 
with hypertension the costs increased by 1,519€ in 10 years (152 € ); whereas the 
total increase in costs in patients with obesity was 1,535 € (153 € ). ConClusions: 
IS has a relevant impact on the costs of management of DM. Hypertension and 
obesity increase these costs even further. Prevention of DM complications and an 
adequate control of risk factors can lead to cost savings for the management of DM. 
Understanding future costs of DM might be valuable for economic evaluations.
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BACkgRound: High prevalence and chronic complications are key determinants 
of management costs of Diabetes Mellitus (DM). Given that DM affects more than 4 
million people in Spain, the costs associated with this disease require an efficient 
management. Cardiovascular diseases are complications associated with DM with 
a major impact in health care budgets. oBjeCtives: Develop a model to predict 
future costs of DM in Spain. Estimate the increase in health care costs in DM patients 
associated with potential cardiovascular diseases. We used the perspective of the 
Regional Health Service in Madrid (public payer). Methods: Foro Gerendia is an 
initiative constituted by health care professional, experts in DM management. A 
Markov model for DM was developed based on the opinion of Foro Gerendia and on 
previous works in this area. A 5-year primary care data registry of 22700 diabetic 
patients in Madrid was used to estimate transition probabilities in the model. Time 
horizon was 10 years. Prices were taken from the health care tariffs published by the 
Regional Health Service in Madrid and from Spanish literature. They were updated to 
2013 price levels and adjusted to subsequent years by a 3% inflation rate. Results: 
Cardiovascular complications included in the model were ischemic heart diseases 
(acute myocardial infarction and angina) and heart failure with a total of 5 health 
states. The estimated increase in costs was € 1,080 per patient in 10 years (€ 108 
per year). Considering an 8% prevalence of DM in Madrid, the increase in costs of 
DM due to cardiovascular diseases would be € 52 million per year. ConClusions: 
Cardiovascular diseases in DM patients have a relevant impact on health care 
expenditure. Prevention of cardiovascular complications can lead to significant 
cost savings for the management of DM. Understanding future costs of DM might 
be valuable in terms of budget allocation and economic evaluation.
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oBjeCtives: Hypercholesterolemia is a risk factor for ciculatory diseases. This study 
estimates the impact of hypercholesterolemia on populations’ health levels and its 
economic impact in Portugal. Methods: The impact on health status is measured 
by the loss of life years adjusted for disability (DALYs - Disability Adjusted Life Years). 
The economic impact analysis includes two components. The first estimates the 
direct costs generated by hypercholesterolemia including consumption of health 
care, social support, and other associated costs (e. g. transport). The second esti-
mates indirect costs, those related to the losses of productivity. The disease burden 
and the costs of illness attributable to hypercholesterolemia include also the com-
plications attributable to this risk factor, namely ischemic stroke and ischemic heart 
disease. In order to estimate the attributable fractions to hypercholesterolemia (total 
cholesterol ≥ 200mg/dL or statin use) of the diseases considered, a microsimulation 
approach was employed by using Framingham equations on the national database 
(VALSIM). In a counterfactual scenario hypercholesterolemia was eliminated from 
these observations and the resulting proportional change in the probability of CV 
events was taken as the hypercholesterolemia attributable fractions. These frac-
tions were used to estimate the contribution of hypercholesterolemia to the burden 
and the annual costs of the aforementioned circulatory diseases. Results: 1,689 
deaths can be attributed to hypercholesterolemia, which corresponds to 1.6% of the 
total deaths in Portugal in 2010. The DALYs resulting from disability and premature 
deaths caused by hypercholesterolemia in 2010 totaled 12,174. The estimated direct 
cost attributable to hypercholesterolemia in 2013 prices is € 320 million (€ 32 million 
for in-patient care and € 288 million for ambulatory care). Indirect costs generated by 
disability attributable to hypercholesterolemia add up to € 198 million. The overall 
costs of disease are therefore estimated at € 518 million, about 0.3% of Portuguese 
GDP. ConClusions: In Portugal, we observed substantial burden and costs associ-
ated with Hypercholesterolemia.
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was significantly reduced versus CG (€ 6,798 vs € 6,954, p< 0.001). PAP recipients had 
a significantly lower 3-year mortality rate versus CG (7.2% vs 10.9%, p< 0.008; rela-
tive risk reduction 33.8%). ConClusions: SA patients with T2DM treated with PAP 
showed significantly reduced mortality and morbidity. Total COI was higher in PAP 
recipients versus CG in the first two years of follow-up, but during year 3 COI was 
significantly lower in the PAP group versus CG. In addition to the known advantages 
of PAP therapy in SA patients with T2DM (e. g. improved glycaemic control), PAP 
therapy may be beneficial from an economic perspective.
PDB41
arE total hEalth CarE EXPEnDiturEs imPaCtED By a nEW DiaBEtEs 
DiagnostiC faCtor: hBa1C?
Bhounsule P.1, Peterson A.M.2
1University of the Sciences in Philadelphia, Philadelphia, PA, USA, 2University of the Sciences, 
Philadelphia, PA, USA
oBjeCtives: To determine differences in total health care expenditures among 
general diabetics and newly diagnosed diabetics before and after HbA1c was 
implemented as the standard diagnostic factor. Methods: Medical Expenditure 
Panel Survey-Household component 2009 and 2011 databases were used. Annual 
health care expenditures formed the dependent variable. Demographic factors, 
comorbidities, prescription drug costs, medical events and utilization variables for 
health care services like visits to office-based, outpatient and inpatient facilities, 
emergency rooms, home health care for 2009 and 2011 formed the independent 
variables. Patients diagnosed within the 2009 and 2011 years, were categorized into 
a dichotomous new diagnosis variable. General linear regression was conducted 
to compare predictors of total diabetes health care expenditures in 2009 and 
2011. Results: The mean total health care expenditure decreased in 2011 com-
pared to 2009 among general diabetics {$10,901 (95%CI= $9,013-$11,836) vs $11,458 
(95%CI= $10,715-$12,201)} and the newly diagnosed ones {$9,462 (95%CI= $6201-
$12,721) vs $8,429 (95%CI= $6793- $10,064)}. Among general diabetics in 2009, total 
expenditures showed significant relationships with prescription drugs, emergency 
room, home health care, outpatient facility and physician services expenses (all 
values p< 0.0001). The 2011 model was similar, but included associations between 
office-based provider visits (p< 0.0001) and previous incidences of heart attacks 
(p= 0.008). In 2009, among newly diagnosed patients, total expenditures were 
significantly associated with home health facilities expenditure (p< 0.0001) as 
opposed to no association in 2011. In both years, prescription medication, emer-
gency room and hospital inpatient facilities expenses contributed to spending. 
Visits to office-based and outpatient department providers, number of home-
health provider days (all values p< 0.0001) and hospital discharges (p= 0.0011) 
impacted total expenditures in 2009 and 2011 respectively. ConClusions: Due 
to the many variables significantly affecting diabetes health expenditures, reduc-
tion in costs could not be solely attributed to the implementation of the HbA1c 
diagnostic criteria. Further research on cost-effectiveness of the HbA1c factor is 
warranted to establish any possible association.
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oBjeCtives: The aim of this study was to assess the direct costs of ambulatory 
treatment associated with types 1 and 2 diabetes mellitus (DM) from the public 
payer perspective in Poland, and to explore the relative contribution of different cost 
components in the total direct cost of DM. Methods: The estimates were based 
on reimbursement data from the years 2012 and 2013 provided by the public payer 
in Poland. Reimbursement costs of insulin, oral anti-diabetes drugs and monitoring 
strips were taken into account. Costs were presented in Polish zloty (PLN). Results: 
Total reimbursement costs for the public payer of anti-diabetes treatment were 1.3 
billion PLN in 2012 and 1.5 billion PLN in 2013, representing 19% and 21% of the 
total Polish reimbursement expenditures in 2012 and 2013, respectively. The highest 
component of anti-diabetes treatment costs was monitoring strips (645 million PLN 
in 2012 and 793 million PLN in 2013, 49% and 52%, respectively). Insulin costs (518 
million PLN in 2012 and 583 million PLN in 2013) and anti-diabetes oral drug costs 
(144 million PLN in 2012 and 155 million PLN in 2013) constitute 38-40% and 10-11% 
of total reimbursement costs, respectively. Regarding insulin, human insulin had a 
larger share of the costs (60-62%) than insulin analogs (38-40%). Premixed human 
insulin (65-66% reimbursement costs) and premixed insulin analogs (47-52% reim-
bursement costs) represent the largest share of the reimbursement costs of human 
insulin and insulin analogs, respectively. Reimbursement costs of biguanides and 
sulphonylureas represent 49-54% and 40-44% of total reimbursement costs of oral 
anti-diabetes drugs, respectively. ConClusions: Total direct costs of diabetes mel-
litus treatment constitute a major part of reimbursement expenditures in Poland 
and are still growing. The main cost driver was reimbursement of monitoring strips, 
and the costs of insulin reimbursement were slightly lower.
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BACkgRound: Diabetes (DM) has a relevant impact on health care budgets mainly 
due to its high prevalence and its chronic and acute complications. Isquemic stroke 
(IS) is one of the macrovascular complications associated with DM and its incidence 
increases with the presence of some risk factors such as hypertension and obe-
sity. oBjeCtives: Develop a model to predict future costs of DM in Spain. Estimate the 
increase in health care costs associated with potential IS in DM patients. Methods: 
Foro Gerendia is an initiative constituted by health care professional, experts in DM 
management. A Markov model for DM was developed based on the opinion of Foro 
Gerendia and on previous works in this area. A 5-year primary care data registry of 
